Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 401–500 of 1,003
Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy
Peng, Y., Liu, J., Inuzuka, H., & Wei, W. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104572 · Cited by 71
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Chen, Q., Munoz, E., & Ashong, D. (2024) · Cancers · doi:10.3390/cancers16030663 · Cited by 71
Deciphering the mystery of thalidomide teratogenicity
Ito, T., & Handa, H. (2012) · Congenital Anomalies · doi:10.1111/j.1741-4520.2011.00351.x · Cited by 71
Self-citationAmare, G. G., Meharie, B. G., & Belayneh, Y. M. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220975825 · Cited by 70
Gourzones-Dmitriev, C., Kassambara, A., Sahota, S., Rème, T., Moreaux, J., Bourquard, P., Hose, D., Pasero, P., Constantinou, A., & Klein, B. (2013) · Cell Cycle · doi:10.4161/cc.25951 · Cited by 61
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 70
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Emerging drug development technologies targeting ubiquitination for cancer therapeutics
Veggiani, G., Gerpe, M. C. R., Sidhu, S. S., & Zhang, W. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.003 · Cited by 63
Oishi, M., Iizumi, Y., Taniguchi, T., Goi, W., Miki, T., & Sakai, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055922 · Cited by 69
Douglass, E. F., Allaway, R. J., Szalai, B., Wang, W., Tian, T., Fernández-Torras, A., Realubit, R., Karan, C., Zheng, S., Pessia, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100492 · Cited by 68
Immunotherapy in myeloma: how far have we come?
Franssen, L. E., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718822660 · Cited by 66
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
Hideshima, T., Ogiya, D., Liu, J., Harada, T., Kurata, K., Bae, J. E., Massefski, W. W., & Anderson, K. C. (2020) · Leukemia · doi:10.1038/s41375-020-0809-x · Cited by 68
Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling
Sharma, A., Khan, H., Singh, T. G., Grewal, A. K., Najda, A., Kawecka-Radomska, M., Kamel, M. S., Altyar, A. E., & Abdel‐Daim, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111971 · Cited by 67
A MedChem toolbox for cereblon-directed PROTACs
Steinebach, C., Sosič, I., Lindner, S., Bricelj, A., Kohl, F., Ng, Y. L. D., Monschke, M., Wagner, K. G., Krönke, J., & Gütschow, M. (2019) · MedChemComm · doi:10.1039/c9md00185a · Cited by 60
Tan, X., Huang, Z., Pei, H., Jia, Z., & Zheng, J. (2024) · iScience · doi:10.1016/j.isci.2024.110712 · Cited by 66
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 66
Screening for molecular glues – Challenges and opportunities
Holdgate, G. A., Bardelle, C., Berry, S. K., Lanne, A., & Cuomo, M. E. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.12.008 · Cited by 67
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Berkley, K., Zalejski, J., Sharma, N., & Sharma, A. K. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00577 · Cited by 66
Hideshima, T., Cottini, F., Ohguchi, H., Jakubikova, J., Gorgun, G., Mimura, N., Tai, Y.-T., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.38 · Cited by 64
Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
McDaniel, J. M., Pinilla-Ibarz, J., & Epling-Burnette, P. K. (2012) · Advances in Hematology · doi:10.1155/2012/513702 · Cited by 62
Mechanisms Mediating Environmental Chemical-Induced Endocrine Disruption in the Adrenal Gland
Martinez-Arguelles, D. B., & Papadopoulos, V. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00029 · Cited by 66
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
Kritharis, A., Coyle, M., Sharma, J., & Evens, A. M. (2015) · Blood · doi:10.1182/blood-2014-11-567792 · Cited by 66
Wu, H., Yao, H., He, C., Jia, Y., Zhu, Z., Xu, S., Li, D., & Xu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.03.019 · Cited by 65
Lessons learned in linking PROTACs from discovery to the clinic
Pike, A., Lee, E. C. Y., Michaelides, I. N., Schade, M., Sharma, A., Scott, J. S., & Srivastava, A. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00784-6 · Cited by 65
Sakamaki, I., Kwak, L. W., Cha, S.-C., Yi, Q., Lerman, B., Chen, J., Surapaneni, S., Bateman, S., & Qin, H. (2014) · Leukemia · doi:10.1038/leu.2013.177 · Cited by 62
Genetic Advances in the Understanding of Microtia
Gendron, C., Schwentker, A. R., & van Aalst, J. A. (2016) · Journal of Pediatric Genetics · doi:10.1055/s-0036-1592422 · Cited by 65
Animal models of endocrine disruption
Patisaul, H. B., Fenton, S. E., & Aylor, D. L. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.011 · Cited by 65
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Yang, H., Chen, X., Li, K., Cheaito, H. A., Yang, Q., Wu, G., Liu, J., & Dou, Q. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.013 · Cited by 65
Li, M.-X., Yang, Y., Zhao, Q., Wu, Y., Song, L., Yang, H., He, M., Gao, H., Song, B.-L., Luo, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00339 · Cited by 61
Ito, T., Yamaguchi, Y., & Handa, H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.012 · Cited by 58
Self-citationIsosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity
Ruchelman, A. L., Man, H., Zhang, W., Chen, R., Capone, L., Kang, J., Parton, A., Corral, L. G., Schafer, P. H., Babusis, D. M., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.10.071 · Cited by 65
Chen, J., Zhu, W., Liu, J., Wang, G., Chen, X., Tan, Y., Xu, W., Qu, L.-W., Li, J., Yang, H.-J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00811-0 · Cited by 64
Causal inference in drug discovery and development
Michoel, T., & Zhang, J. D. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103737 · Cited by 64
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation
Norris, S. H., Ba, X., Rhodes, J., Huang, D., Khambatta, G., Buenviaje, J., Nayak, S. K., Meiring, J., Reiss, S. M., Xu, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01848 · Cited by 64
Update on Embryology of the Upper Limb
Al-Qattan, M. M., & Kozin, S. H. (2013) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2013.03.018 · Cited by 64
Overview of Chirality and Chiral Drugs
Lin, G., Zhang, J., & Cheng, J. (2011) · Wiley eBooks · doi:10.1002/9781118075647.ch1 · Cited by 64
Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216
Teng, M., Lu, W., Donovan, K. A., Sun, J., Krupnick, N. M., Nowak, R. P., Li, Y.-D., Sperling, A. S., Zhang, T., Ebert, B. L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01832 · Cited by 63
Molecular glues and induced proximity: An evolution of tools and discovery
Robinson, S. A., Co, J., & Banik, S. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.04.001 · Cited by 63
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 63
Liu, H., Ding, X., Liu, L., Mi, Q., Zhao, Q., Shao, Y., Ren, C., Chen, J., Kong, Y., Qiu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113645 · Cited by 63
Zhang, L., Qu, Y., Tang, J., Chen, D., Fu, X., Mao, M., & Mu, D. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.007 · Cited by 63
Huang, S.-Y., Lin, C.-W., Lin, H.-H., Yao, M., Tang, J.-L., Wu, S.-J., Chen, Y.-C., Lu, H.-Y., Hou, H.-A., Chen, C.-Y., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2063-7 · Cited by 62
“Although the substrates of CRBN, as a putative substrate receptor of the CRBN-based E3ULC, remain unidentified, the CRBN-based E3ULC has auto-ubiquitination activity in the absence of their specific substrates, which is inhibited by thalidomide [4], suggesting that binding of thalidomide to CRBNmay inhibit the functio…”
BackgroundInfluentialThe Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets
Abramson, H. N. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.015 · Cited by 62
Heider, M., Eichner, R., Stroh, J., Morath, V., Kuisl, A., Zecha, J., Lawatscheck, J., Baek, K., Garz, A.-K., Rudelius, M., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.046 · Cited by 62
Recent Advances in PROTAC-Based Antiviral Strategies
Ahmad, H., Zia, B., Husain, H., & Husain, A. (2023) · Vaccines · doi:10.3390/vaccines11020270 · Cited by 62
Novel approaches to targeted protein degradation technologies in drug discovery
Xue, Y., Bolinger, A. A., & Zhou, J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2187777 · Cited by 62
Fast-acting chemical tools to delineate causality in transcriptional control
Jaeger, M. G., & Winter, G. E. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.015 · Cited by 59
Chen, Y.-A., Peng, Y.-J., Hu, M.-C., Huang, J.-J., Chien, Y.-C., Wu, J.-T., Chen, T.-Y., & Tang, C.-Y. (2015) · Scientific Reports · doi:10.1038/srep10667 · Cited by 61
Covalent drugs targeting histidine – an unexploited opportunity?
Che, J., & Jones, L. H. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00258b · Cited by 61
Can we change the disease biology of multiple myeloma?
Borrello, I. (2012) · Leukemia Research · doi:10.1016/s0145-2126(12)70003-6 · Cited by 61
Rychak, E., Mendy, D., Shi, T., Ning, Y., Leisten, J., Lu, L., Miller, K., Narla, R. K., Orlowski, R. Z., Raymon, H. K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13905 · Cited by 60
Update on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 61
Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
Naito, M., Ohoka, N., Shibata, N., & Tsukumo, Y. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00849 · Cited by 60
Geiger, T. M., Schäfer, S. C., Dreizler, J. K., Walz, M., & Hausch, F. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100018 · Cited by 52
Steinebach, C., Bricelj, A., Murgai, A., Sosič, I., Bischof, L., Ng, Y. L. D., Heim, C., Maiwald, S. A., Proj, M., Voget, R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00851 · Cited by 60
The temporal dynamics of vertebrate limb development, teratogenesis and evolution
Zeller, R. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.04.014 · Cited by 60
Cereblon binding molecules in multiple myeloma
Kortüm, K. M., Zhu, Y. X., Shi, C., Jedlowski, P. M., & Stewart, A. K. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.03.003 · Cited by 60
Hideshima, T., Cottini, F., Nozawa, Y., Seo, H., Ohguchi, H., Samur, M., Cirstea, D. D., Mimura, N., Iwasawa, Y., Richardson, P. G. G., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738500 · Cited by 60
Protein-slaying drugs could be the next blockbuster therapies
Scudellari, M. (2019) · Nature · doi:10.1038/d41586-019-00879-3 · Cited by 60
HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action
Imai, Y., Hirano, M., Kobayashi, M., Futami, M., & Tojo, A. (2019) · Cancers · doi:10.3390/cancers11040475 · Cited by 60
Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery
Jung, H. J., & Kwon, H. J. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0618-3 · Cited by 60
Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Salerno, A., Seghetti, F., Caciolla, J., Uliassi, E., Testi, E., Guardigni, M., Roberti, M., Milelli, A., & Bolognesi, M. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00302 · Cited by 59
Proteomic characterization of post-translational modifications in drug discovery
Zhai, L., Chen, K., Hao, B., & Tan, M. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01017-y · Cited by 59
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Mi, D., Li, Y., Gu, H., Li, Y., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115444 · Cited by 59
Clinical Translation of Targeted Protein Degraders
Kong, N. R., & Jones, L. H. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2985 · Cited by 59
PAX3-FOXO1: Zooming in on an “undruggable” target
Wachtel, M., & Schäfer, B. W. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.006 · Cited by 59
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 54
Kiss, L., Clift, D., Renner, N., Neuhaus, D., & James, L. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21443-6 · Cited by 59
Proteomics in the pharmaceutical and biotechnology industry: a look to the next decade
Lill, J. R., Mathews, W. R., Rose, C. M., & Schirle, M. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1962300 · Cited by 59
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)
Chotitumnavee, J., Yamashita, Y., Takahashi, Y., Takada, Y., Iida, T., Oba, M., Itoh, Y., & Suzuki, T. (2022) · Chemical Communications · doi:10.1039/d2cc00272h · Cited by 59
Self-citationWhere We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma
Bergsagel, P. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.199 · Cited by 53
Cereblon in health and disease
Kim, H. K., Ko, T. H., Nyamaa, B., Lee, S. R., Kim, N., Ko, K. S., Rhee, B. D., Park, C., Nilius, B., & Han, J. (2016) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-016-1854-1 · Cited by 58
Akuffo, A. A., Alontaga, A. Y., Metcalf, R., Beatty, M. S., Becker, A., McDaniel, J. M., Hesterberg, R. S., Goodheart, W. E., Gunawan, S., Ayaz, M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816868 · Cited by 53
Jarque, S., Rubio-Brotons, M., Ibarra, J., Ordóñez, V., Dyballa, S., Miñana, R. M., & Terriente, J. (2020) · Reproductive Toxicology · doi:10.1016/j.reprotox.2020.08.004 · Cited by 58
ALDH2 Mediates 5-Nitrofuran Activity in Multiple Species
Zhou, L., Ishizaki, H., Spitzer, M., Taylor, K. L., Temperley, N. D., Johnson, S. L., Brear, P., Gautier, P. E., Zeng, Z., Mitchell, A. F., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.05.017 · Cited by 58
Nishiguchi, G., Mascibroda, L. G., Young, S. M., Caine, E. A., Abdelhamed, S., Kooijman, J. J., Miller, D. J., Das, S., McGowan, K., Mayasundari, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44698-1 · Cited by 57
Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy
Liu, Q., Aminu, B., Roscow, O., & Zhang, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020791 · Cited by 57
Liu, C., Zhao, Y., Zhang, T.-S., Tao, C., Fei, W., Zhang, S., & Li, M. (2023) · Nature Communications · doi:10.1038/s41467-023-39462-w · Cited by 57
Routes to molecular glue degrader discovery
Liu, Y., Bai, J., Li, D., & Cang, Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.12.006 · Cited by 57
Liu, Y., Huang, X., He, X., Zhou, Y., Jiang, X., Chen‐Kiang, S., Jaffrey, S. R., & Xu, G. (2015) · The FASEB Journal · doi:10.1096/fj.15-274050 · Cited by 57
Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection)
Walsh, D. S., Portaels, F., & Meyers, W. M. (2010) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32833c2209 · Cited by 57
Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer
Ren, S., Xu, C., Cui, Z., Yu, Y., Xu, W., Wang, F., Lu, J., Wei, M., Lu, X. L., Gao, X., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0885-0 · Cited by 57
Stahl, M. F., & Zeidan, A. M. (2017) · Cancer · doi:10.1002/cncr.30585 · Cited by 57
Burslem, G. M., Ottis, P., Jaime‐Figueroa, S., Morgan, A., Cromm, P. M., Toure, M., & Crews, C. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201800271 · Cited by 52
Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders
Gosavi, P. M., Ngan, K. C., Yeo, M. J. R., Su, C., Li, J., Lue, N. Z., Hoenig, S. M., & Liau, B. B. (2022) · ACS Central Science · doi:10.1021/acscentsci.1c01603 · Cited by 56
Thakurta, A., Gandhi, A. K., Waldman, M. F., Bjorklund, C., Ning, Y., Mendy, D., Schafer, P., Lopez-Girona, A., Lentzsch, S., Schey, S. A., et al. (2014) · Leukemia · doi:10.1038/leu.2013.315 · Cited by 56
Flight for fish in drug discovery: a review of zebrafish-based screening of molecules
Dash, S. N., & Patnaik, L. (2023) · Biology Letters · doi:10.1098/rsbl.2022.0541 · Cited by 56
New Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 56
Timme‐Laragy, A. R., Karchner, S. I., & Hahn, M. E. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-867-2_5 · Cited by 56
Intravitreal Bevacizumab for Retinopathy of Prematurity
Harder, B. C., von Baltz, S., Jonas, J. B., & Schlichtenbrede, F. C. (2011) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0060 · Cited by 56
Deletion 5q MDS: Molecular and therapeutic implications
Komrokji, R. S., Padron, E., Ebert, B. L., & List, A. F. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.10.013 · Cited by 56
Vitamin K2 Covalently Binds to Bak and Induces Bak-Mediated Apoptosis
Karasawa, S., Azuma, M., Kasama, T., Sakamoto, S., Kabe, Y., Imai, T., Yamaguchi, Y., Miyazawa, K., & Handa, H. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.082602 · Cited by 56
Self-citationCereblon negatively regulates TLR4 signaling through the attenuation of ubiquitination of TRAF6
Min, Y., Wi, S. M., Kang, J., Yang, T., Park, C., Park, S., Chung, S., Shim, J., Chun, E., & Lee, K. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.226 · Cited by 56
Ubiquitin-Dependent Regulation of Stem Cell Biology
Werner, A. A., Manford, A. G., & Rapé, M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.04.002 · Cited by 56
Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC)
Krajcovicova, S., Jorda, R., Hendrychova, D., Krystof, V., & Soural, M. (2019) · Chemical Communications · doi:10.1039/c8cc08716d · Cited by 53
Targeting cereblon in hematologic malignancies
Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55
Rej, R. K., Allu, S. R., Roy, J., Acharyya, R. K., Kiran, I. N. C., Addepalli, Y., & Dhamodharan, V. (2024) · Pharmaceuticals · doi:10.3390/ph17040494 · Cited by 55
A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation
Basu, A. A., Zhang, C., Riha, I. A., Magassa, A., Campos, M. A. L., Caldwell, A. G., Ko, F., & Zhang, X. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01655-9 · Cited by 55
Nitric oxide rescues thalidomide mediated teratogenicity
Siamwala, J. H., Veeriah, V., Priya, M. K., Rajendran, S., Saran, U., Sinha, S., Nagarajan, S., T, P., & Chatterjee, S. (2012) · Scientific Reports · doi:10.1038/srep00679 · Cited by 54
Pericytes as targets in hereditary hemorrhagic telangiectasia
Thalgott, J. H., Dos-Santos-Luis, D., & Lebrin, F. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00037 · Cited by 55
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.